Clinical Experience in Managing AEs in GPRC5D Therapy

Opinion
Video

Mary Steinbach, APRN, shares her experience in managing dysgeusia and nail- and skin-related toxicities seen in patients with multiple myeloma who receive talquetamab.

Recent Videos
4 experts in this video
4 experts in this video
Andrezj Jakubowiak, MD, PhD, prioritizes KRd-based regimens for the treatment of high-risk newly diagnosed disease in the post-transplant setting.
Although a similar proportion achieved MRD negativity at the 10 to the –6 power, not enough studies have analyzed MRD at this level for multiple myeloma.
Unique toxicities presented with talquetamab tend to get progressively better as the treatment course continues, according to Prerna Mewawalla, MD.
Related Content